GLPwatch
Cardiovascular risk reduction
Approved indication
Last updated 2026-05-28 15:46 UTCFDA-approved GLP-1 drugs Ozempic, Trulicity, Victoza, and Wegovy are indicated for cardiovascular risk reduction, with semaglutide specifically highlighted in research such as the SELECT trial for its role in managing cardiovascular-kidney-metabolic syndrome.
AI summary of the sources below.
How Cardiovascular risk reduction connects
- Drugs OzempicTrulicityVictozaWegovy
- Molecules SemaglutideDulaglutideLiraglutide
- Research 1,284 papers
Approved GLP-1 drugs (4)
Research (50)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
- Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
- The Discovery and Development of Liraglutide and Semaglutide.
- Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
- GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
- Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
- Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
- Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.
- Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
- Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.
- Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
- The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
- Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
Common questions
- Which GLP-1 drugs are FDA-approved for Cardiovascular risk reduction?
- Ozempic, Trulicity, Victoza and Wegovy are FDA-approved for cardiovascular risk reduction.
- Is there research on GLP-1 drugs for Cardiovascular risk reduction?
- GLPwatch tracks 1284 research papers on GLP-1 drugs and cardiovascular risk reduction. This research is investigational and does not imply FDA approval.